US FDA Green-Lights Medtronic's CoreValve Evolut For Intermediate Risk

 
• By Reed Miller

The approval, based on the results of the SURTAVI trial, comes a few months ahead of analysts' expectations and is welcome news for Medtronic in its effort to keep pace with TAVR leader Edwards in the US market.

Core Valve In Situ
CoreValve System in action. • Source: Medtronic PLC

More from Approvals

More from Policy & Regulation